b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">\n        <PMID Version="1">32258443</PMID>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>04</Month>\n            <Day>09</Day>\n        </DateRevised>\n        <Article PubModel="Electronic-eCollection">\n            <Journal>\n                <ISSN IssnType="Electronic">2405-6308</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>22</Volume>\n                    <PubDate>\n                        <Year>2020</Year>\n                        <Month>May</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Clinical and translational radiation oncology</Title>\n                <ISOAbbreviation>Clin Transl Radiat Oncol</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Patient reported outcomes following proton pencil beam scanning vs. passive scatter/uniform scanning for localized prostate cancer: Secondary analysis of PCG 001-09.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>50-54</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ctro.2020.03.003</ELocationID>\n            <Abstract>\n                <AbstractText Label="Background" NlmCategory="UNASSIGNED">Although pencil beam scanning (PBS) is the most conformal method for proton beam therapy (PBT) delivery, it is unknown if outcomes differ compared to treatment with passive scatter/uniform scanning (PS/US). This analysis compares patient reported outcomes (PRO) changes following PBS and PS/US for prostate cancer (PC) in a prospective multicenter registry study.</AbstractText>\n                <AbstractText Label="Methods" NlmCategory="UNASSIGNED">We evaluated PROs with the Expanded Prostate Cancer Index Composite (EPIC) instrument for men with localized PC enrolled in PCG 001-09 (NCT01255748). PROs were assessed at baseline and through 12\xc2\xa0months of follow-up. We compared mean changes in EPIC scores, as well as the proportions of men experiencing a one- and two-fold minimally important difference (MID) in domain scores, between PBS and PS/US. Multivariate analyses (MVAs) were performed to further evaluate the association between proton modality and PRO changes.</AbstractText>\n                <AbstractText Label="Results" NlmCategory="UNASSIGNED">Three-hundred-and-four men completed EPIC at baseline; 72 received PBS and 232 received PS/US. The average quality-of-life (QOL) declines from baseline through 12\xc2\xa0months did not significantly differ between the two groups. The proportion of men reporting a 1-MID decline at 12\xc2\xa0months for PBS and PS/US was 34.3% and 27.4%, respectively, for urinary QOL (<i>P</i>\xc2\xa0=\xc2\xa00.27); 40. 1% and 40.9% for bowel QOL (<i>P</i>\xc2\xa0=\xc2\xa00.36); and 30. 1% and 36.6% for sexual QOL (<i>P</i>\xc2\xa0=\xc2\xa00.94). Corresponding 2-MID declines for PBS and PS/US were observed in 26.9% and 13.2% of men for urinary QOL (<i>P</i>\xc2\xa0=\xc2\xa00.01), 35.3% and 29.1% for bowel QOL (<i>P</i>\xc2\xa0=\xc2\xa00.33); and 16.4% and 18.1% for sexual QOL (<i>P</i>\xc2\xa0=\xc2\xa00.76). The association between proton modality and 2-MID changes in urinary QOL at 12-months remained significant on MVA (P\xc2\xa0=\xc2\xa00.007).</AbstractText>\n                <AbstractText Label="Conclusions" NlmCategory="UNASSIGNED">The results of this analysis show differences between PBS and PS/US with regards to two-fold MID changes in urinary function at 12\xc2\xa0months, but no differences for average score declines over time. Future studies evaluating PRO measures between the two PBT modalities are warranted.</AbstractText>\n                <CopyrightInformation>\xc2\xa9 2020 The Authors.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Mishra</LastName>\n                    <ForeName>Mark V</ForeName>\n                    <Initials>MV</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, United States.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Khairnar</LastName>\n                    <ForeName>Rahul</ForeName>\n                    <Initials>R</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD, United States.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Bentzen</LastName>\n                    <ForeName>S\xc3\xb8ren M</ForeName>\n                    <Initials>SM</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Epidemiology &amp; Public Health, Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD, United States.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Larson</LastName>\n                    <ForeName>Gary</ForeName>\n                    <Initials>G</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>ProCure Proton Therapy Center, Oklahoma City, OK, United States.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Tsai</LastName>\n                    <ForeName>Henry</ForeName>\n                    <Initials>H</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>ProCure Proton Therapy Center, Somerset, NJ, United States.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Sinesi</LastName>\n                    <ForeName>Christopher</ForeName>\n                    <Initials>C</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Hampton University Proton Therapy Institute, Hampton, VA, United States.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Vargas</LastName>\n                    <ForeName>Carlos</ForeName>\n                    <Initials>C</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Radiation Oncology, Mayo Clinic Arizona, Phoenix, AZ, United States.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Laramore</LastName>\n                    <ForeName>George</ForeName>\n                    <Initials>G</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>University of Washington, Department of Radiation Oncology, Seattle, WA, United States.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Rossi</LastName>\n                    <ForeName>Carl</ForeName>\n                    <Initials>C</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>California Protons Cancer Therapy Center, San Diego, CA, United States.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Rosen</LastName>\n                    <ForeName>Lane</ForeName>\n                    <Initials>L</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Willis-Knighton Proton Therapy Center, Shreveport, LA, United States.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Sun</LastName>\n                    <ForeName>Kai</ForeName>\n                    <Initials>K</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, United States.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Hartsell</LastName>\n                    <ForeName>William</ForeName>\n                    <Initials>W</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Northwestern Medicine Chicago Proton Center, Warrenville, IL, United States.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2020</Year>\n                <Month>03</Month>\n                <Day>07</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>Ireland</Country>\n            <MedlineTA>Clin Transl Radiat Oncol</MedlineTA>\n            <NlmUniqueID>101713416</NlmUniqueID>\n            <ISSNLinking>2405-6308</ISSNLinking>\n        </MedlineJournalInfo>\n        <CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2019</Year>\n                <Month>12</Month>\n                <Day>30</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="revised">\n                <Year>2020</Year>\n                <Month>03</Month>\n                <Day>01</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2020</Year>\n                <Month>03</Month>\n                <Day>04</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2020</Year>\n                <Month>4</Month>\n                <Day>8</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2020</Year>\n                <Month>4</Month>\n                <Day>8</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2020</Year>\n                <Month>4</Month>\n                <Day>8</Day>\n                <Hour>6</Hour>\n                <Minute>1</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>epublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">32258443</ArticleId>\n            <ArticleId IdType="doi">10.1016/j.ctro.2020.03.003</ArticleId>\n            <ArticleId IdType="pii">S2405-6308(20)30016-1</ArticleId>\n            <ArticleId IdType="pmc">PMC7125313</ArticleId>\n        </ArticleIdList>\n        <ReferenceList>\n            <Reference>\n                <Citation>J Clin Epidemiol. 2008 Feb;61(2):102-9</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">18177782</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Urology. 2015 Jan;85(1):101-5</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25530370</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):228-235</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28068231</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>N Engl J Med. 2016 Oct 13;375(15):1425-1437</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27626365</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Natl Cancer Inst. 2013 Jan 2;105(1):25-32</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">23243199</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):946-53</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">24139077</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Lancet Oncol. 2006 Nov;7(11):903-9</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">17081915</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Clin Transl Radiat Oncol. 2019 Aug 31;19:80-86</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">31650043</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Acta Oncol. 2018 Sep;57(9):1259-1264</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">29726722</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Acta Oncol. 2017 Jun;56(6):761-762</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28464735</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Int J Radiat Oncol Biol Phys. 2017 Apr 1;97(5):976-985</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28209443</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Urology. 2000 Dec 20;56(6):899-905</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">11113727</ArticleId>\n                </ArticleIdList>\n            </Reference>\n        </ReferenceList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'